Onkologie. 2018:12(4):182-184 | DOI: 10.36290/xon.2018.033

Treatment of patients with non-small cell lung cancer with ALK rearrangement

Ondřej Venclíček
Klinika nemocí plicních a tuberkulózy LF MU a FN Brno

The article presents a brief summary of the basic theoretical knowledge of non-small cell lung cancer harbouring mutation in theanaplastic lymphomkinase (ALK) gene. It also discusses the current possibilities of oncology therapy targeting the ALK mutation –the inhibitors of ALK signaling pathway and current options of their use in the Czech Republic.

Keywords: non small cell lung cancer (NSCLC), anaplastic lymphom kinase (ALK), biological therapy, tyrosinkinase inhibitors (TKI)

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Venclíček O. Treatment of patients with non-small cell lung cancer with ALK rearrangement. Onkologie. 2018;12(4):182-184. doi: 10.36290/xon.2018.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České re-publice [online]. Masarykova univerzita, [2005], [cit. 2018-5-30]. Dostupný z: http://www.svod.cz. Verze 7.0. 2007: 1802-8861.
    2. Dušek L, Májek O, Krejčí D, et al. Epidemiologie zhoubných nádorů plic, průdušnice a průdušek v ČR. In: Skřičková J a kol. Základy moderní pneumoonkologie 2. vydání. Maxdorf Praha 2017: 20-47.
    3. Du X, Shao Y, Qin H, et al. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer [online]. 2018; 9(4): 423-430 [cit. 2018-05-30]. Dostupné z: https://doi.org/10.1111/1759-7714.12613. Go to original source... Go to PubMed...
    4. Soda M, Young LC, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature [online]. 2007; 448(7153): 561-566 [cit. 2018-05-30]. Dostupné z: http://dx.doi.org/10.1038/nature05945. Go to original source... Go to PubMed...
    5. Laffert MV, Warth A, Penzel R, et al. Anaplastic lymphoma kinase (ALK) gene rear-rangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing. Lung Cancer [online]. 2013; 81(2): 200-206 [cit. 2018-05-30]. Dostupné z: https://doi.org/10.1016/j.lungcan.2013.04.015. Go to original source... Go to PubMed...
    6. Zer A, Moskovitz M, Hwang DM, et al. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. Clin Lung Cancer [online]. 2017; 18(2): 156-161 [cit. 2018-05-30]. Dostupné z: https://doi.org/10.1016/j.cllc.2016.10.007. Go to original source... Go to PubMed...
    7. Česká pneumologická a ftizeologická společnost: Sekce pneumoonkologická [online]. [cit. 2018-05-30]. Dostupné z: http://www.pneumologie.cz/stranka/56/sekce-pneumoonkologicka/.
    8. Solomon BJ, Mok T, Kim D, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med [online]. 2014; 371(23): 2167-77 [cit. 2018-05-30]. Dostupné z: DOI: 10.1056/NEJMoa1408440. Go to original source... Go to PubMed...
    9. Katayama R. Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. Pharmacol Ther [online]. 2017; 177: 1-8 [cit. 2018-05-30]. Dostupné z: https://doi.org/10.1016/j.pharmthera.2017.02.015. Go to original source... Go to PubMed...
    10. Soria J, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemothe-rapy in advanced ALK - rearranged non-small-cell lung cancer (ASCEND-4): A ran-domised, open-label, phase 3 study. Lancet [online]. 2017; 389(10072): 917-929 [cit. 2018-05-30]. Dostupné z: DOI:10.1016/S0140-6736(17)30123-X. Go to original source... Go to PubMed...
    11. Zhang I, Zaorsky NG, Palmer JD, et al. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol [online]. 2015; 16(13): e510-e521 [cit. 2018-05-30]. Dostupné z: https://doi.org/10.1016/S1470-2045(15)00013-3. Go to original source... Go to PubMed...
    12. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med [online]. 2017; 377(9): 829-838 [cit. 2018-05-30]. Dostupné z: DOI: 10.1056/NEJMoa1704795. Go to original source... Go to PubMed...
    13. Camidge DR, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol [online]. 2018; 36(15_suppl): 9043-9043 [cit. 2018-06-19]. Dostupné z: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9043. Go to original source...
    14. Abraham J. Brigatinib approval yields additional treatment options for crizotinib-resistant, ALK-positive NSCLC patients. J Community Support Oncol [online]. 2017, 15(6), e291 - e293 [cit. 2018-05-30]. Dostupné z: DOI: 10.12788/jcso.0380. Go to original source...
    15. Camidge DR, Kim DW, Tiseo M, et al. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol [online]. 2018, JCO2017775841 [cit. 2018-05-30]. Dostupné z: DOI: 10.1200/JCO.2017.77.5841. Go to original source... Go to PubMed...
    16. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: An international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol [online]. 2017; 18(12): 1590-1599 [cit. 2018-05-30]. Dostupné z: DOI:10.1016/S1470-2045(17)30680-0. Go to original source... Go to PubMed...
    17. Státní ústav pro kontrolu léčiv. Státní ústav pro kontrolu léčiv [online]. Praha: SÚKL, 2010 [cit. 2018 05 30]. Dostupné z: http://www.sukl.cz/.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.